Clinical Trial Update: A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial update for SHR-1316 in combination with chemotherapy versus placebo in resectable non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-1316

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-Small-Cell Lung Cancer | Phase 3 | Status: RECRUITING